Zhang et al. (2022) found that SHMT2 was upregulated in oral squamous cell carcinoma and that strong expression was linked to poor prognosis. More importantly, the role of SHMT2 has been reported in glioma (Kim et al., 2015), lymphoma (Wilke et al., 2022) and bladder cancer (Zhang & Yang, 2021). This evidence concerns the gene SHMT2 and lymphoma.